Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Sirnaomics, founded in 2007 and headquartered in Gaithersburg, Maryland, is a biopharmaceutical company specializing in the development of RNA interference (RNAi) therapeutics. The company focuses on creating innovative treatments for fibrotic diseases, cancer, and other medical conditions. Sirnaomics' lead candidate, STP705, is an anti-fibrosis siRNA therapeutic that has shown promising results in various animal models for treating skin hypertrophic scars, liver fibrosis, and lung fibrosis.
Since its inception, Sirnaomics has raised a total of $267.68 million in funding, demonstrating significant investor interest in its potential. The company's unique dual-targeted inhibitory approach to RNAi therapeutics sets it apart in the competitive biotechnology landscape.
As of now, we don't have any concrete information regarding Sirnaomics' IPO prospects. The company is currently listed on the Hong Kong Stock Exchange (HK: 02257), but there are no confirmed reports or official statements about plans for listing on other exchanges. Investors interested in Sirnaomics should keep an eye on official company announcements and financial news sources for any updates on potential IPO plans or changes in the company's public trading status.
It's important to note that various factors can influence a company's decision to pursue an IPO, including market conditions, financial performance, and strategic goals. As with any investment opportunity, potential investors should conduct thorough research and consider seeking advice from financial professionals before making investment decisions related to Sirnaomics or any other company.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Sirnaomics' IPO prospects remain uncertain, investors eager to explore opportunities in the biotechnology and RNA therapeutics space don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the biotech sector, like Sirnaomics, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from their growth and innovation before they hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
